“…Chemoresponsiveness of congenital fibrosarcoma is unclear [6,30], however neoadjuvant chemotherapy may be used, in an attempt to decrease tumor size and reduce the surgical morbidity. Chemotherapy also has been used for unresectable lesions [3,16,17,22,27,37]. The most common regimen used combines vincristine, actinomycin D, and cyclophosphamide (VAC) [6,30]; its side effect is well established and is tolerable in infants [10,22,23].…”